Table 2.
Substance use history and treatment characteristics of Black adults receiving buprenorphine for opioid use disorder
| Substance use history and treatment characteristics | Total N (%) N = 98 |
Men N (%) N = 47 |
Women N (%) N = 52 |
|---|---|---|---|
| Type of opioid use | |||
|
Heroin only Prescription opioid only Both |
72 (73.5) 8 (8.2) 18 (18.4) |
41 (87.2) 1 (2.1) 5 (10.6) |
31 (60.8) 7 (13.7) 13 (25.5) |
|
Most serious route of opioid use Injection Nasal Oral Not reported |
42 (42.9) 40 (40.8) 8 (8.2) 8 (8.2) |
23 (48.9) 19 (40.4) 1 (2.1) 4 (8.5) |
19 (37.3) 21 (41.2) 7 (13.7) 4 (7.8) |
| Daily opioid use at treatment entry (nonprescription use) | 81 (82.7) | 40 (85.1) | 41 (80.4) |
| Age onset opioid use (mean ± SD) | 26.0 ± 10.4 | 25.4 ± 11.0 | 26.6 ± 10.0 |
| History overdose | 22 (22.4) | 13 (27.7) | 9 (17.6) |
| Lifetime polysubstance use | 92 (93.9) | 46 (97.9) | 46 (90.2) |
| Prior self-help group (AA/NA) | 11 (11.2) | 6 (12.8) | 5 (9.8) |
| aPrior specialty SUD treatment | 70 (71.4) | 35 (74.5) | 35 (68.6) |
| bLong-term MOUD with buprenorphine (≥1 year) | 58 (59.2) | 25 (53.2) | 33 (64.7) |
| bLength of current treatment episode (Mean ± SD; days) | 406.9 ± 249.4 | 358.6 ± 247.0 | 451.4 ± 245.6 |
Notes: SD, standard deviation; AA, alcoholics anonymous; NA, narcotics anonymous
aPrior specialty SUD treatment includes inpatient/residential, intensive outpatient, medication for OUD, and behavioral health services for SUD
bAt time of baseline survey completion